Significant proportion of cancer drugs lack proof of added benefit
Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited (“fast track”) pathways, finds a study published by The BMJ today.
And despite pharmaceutical industry claims that high drug prices are needed to offset research and development (R&D) costs, the results show that more than half of these drugs, including those with minimal or no added benefit, recover R&D expenses within three years.
As such, the researchers call for better alignment between regulatory and reimbursement processes, particularly for drugs approved through expedited pathways, to promote development ...










